论文部分内容阅读
在糖尿病普查、筛选和评价糖尿病控制程度及指导用药过程中,常以尿糖多少来初步筛选和评价糖尿病控制的好坏。应用尿糖试纸来评价血糖控制程度和指导用药还是一种简单普遍应用的手段。然而我们在糖尿病临床诊疗中发现,大多数病人的肾糖阈各不相同,且差异较大。在这种情况下,评价糖尿病控制好坏以尿糖“加号”的多少指导用药是不可靠的,甚至是危险的。此时医生的思路是以正常人肾糖阈来估计尿糖和血糖关系的。对一个肾糖阈低的病人,用药后可造成低血糖,对一个肾糖阈高的病人,又往往造成降糖药物用量不足而长期处于高血糖状态,且可使糖尿病慢性血管并发症发病率增加或进展较快,使病人过早地丧失劳动能力,或过早地死于糖尿病慢性并发症。
In the diabetes census, screening and evaluation of the degree of diabetes control and guide the process of medication, often how much urine to initial screening and evaluation of the quality of diabetes control. Application of urine test strips to assess the degree of glycemic control and guide the use of drugs or a simple universal means. However, we found in clinical diagnosis and treatment of diabetes, most patients with different threshold of renal glucose, and the difference is bigger. In such cases, it is not reliable or even dangerous to rate how much diabetes control is good with “plus” urine. At this point the idea of the doctor is based on normal renal sugar threshold to estimate the relationship between blood sugar and urine. A low threshold for patients with renal sugar, can cause hypoglycemia after treatment, a high threshold for patients with renal sugar, often resulting in hypoglycemic drugs and long-term high blood sugar in the state, and can make the incidence of diabetic chronic vascular complications Increase or progress faster, so that patients prematurely incapacitated, or premature death from chronic complications of diabetes.